NanoViricides Finalizes $6 Million Funding Round

NanoViricides, Inc. has completed a $6 million registered direct offering with a healthcare institutional investor. This deal includes the sale of 3,571,429 shares of common stock at $1.68 per share. Concurrently, the company issued Series A and B Warrants in a private placement. The Series A Warrants are priced at $1.75 and expire two years from issuance, while the Series B Warrants, issued at $2.00, expire after 5.5 years.

The funds raised will support working capital and general corporate activities. The arrangement was orchestrated by A.G.P./Alliance Global Partners. The securities were filed under an effective registration statement with the SEC in compliance with regulations.

NanoViricides focuses on creating antiviral treatments and advancing clinical trials for their lead drug candidate, NV-387, targeting multiple viral infections.